P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

por Kastritis, E., Minnema, M. C., Dimopoulos, M. A., Merlini, G., Theodorakakou, F., Fotiou, D., Huart, A., Belhadj, K., Gkolfinopoulos, S., Manousou, K., Sonneveld, P., Palladini, G.
Publicado 2022

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

por Kastritis, E., Palladini, G., Dimopoulos, M. A., Jaccard, A., Merlini, G., Theodorakakou, F., Fotiou, D., Minnema, M. C., Wechalekar, A., Gkolfinopoulos, S., Manousou, K., Sonneveld, P., Schönland, S.
Publicado 2022

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

por Terpos, E, Migkou, M, Christoulas, D, Gavriatopoulou, M, Eleutherakis-Papaiakovou, E, Kanellias, N, Iakovaki, M, Panagiotidis, I, Ziogas, D C, Fotiou, D, Kastritis, E, Dimopoulos, M A
Publicado 2016

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

por Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Gavriatopoulou, M., Theodorakakou, F., Fotiou, D., Syrigou, R. E., Migkou, M., Roussou, M., Eleutherakis-Papaiakovou, E., Kastritis, E., Dimopoulos, M. A, Terpos, E.
Publicado 2023

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Malandrakis, P., Spiliopoulou, V., Syrigou, R.E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Syrigou, R., Eleutherakis-Papaiakovou, E., Gkolfinopoulos, S., Manousou, K., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

por Dimopoulos, M A, Roussou, M, Gavriatopoulou, M, Fotiou, D, Ziogas, D C, Migkou, M, Panagiotidis, I, Eleutherakis-Papaiakovou, E, Kanellias, N, Psimenou, E, Marinaki, S, Bacharaki, D, Mparmparoussi, D, Matsouka, C, Giannouli, S, Terpos, E, Kastritis, E
Publicado 2017

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

por Malandrakis, P., Ntanasis-Stathopoulos, I., Kostopoulos, I.V., Roussakis, P., Eleutherakis-Papaiakovou, E., Panteli, C., Angelis, N., Spiliopoulou, V., Orologas-Stavrou, N., Theodorakakou, F., Fotiou, D., Migkou, M., Gavriatopoulou, M., Kastritis, E., Tsitsilonis, O.E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

por Kastritis, E, Gavriatopoulou, M, Roussou, M, Fotiou, D, Ziogas, D C, Migkou, M, Eleutherakis-Papaiakovou, E, Panagiotidis, I, Kanellias, N, Psimenou, E, Papadopoulou, E, Pamboucas, C, Manios, E, Gakiopoulou, H, Ntalianis, A, Tasidou, A, Giannouli, S, Terpos, E, Dimopoulos, M A
Publicado 2017